Skip to main content
SpringerLink
Log in

Anti-cd19-chimeric-antigen-receptor-t-cell-therapy-tianjin-mycure-medical-technology

Lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • He L, et al. Early Hyperprogression of Lymphoma Detected by 18 F-FDG PET/CT After Chimeric Antigen Receptor T-Cell Therapy. Clinical Nuclear Medicine 48: 256-258, No. 3, Mar 2023. Available from: URL: http://doi.org/10.1097/RLU.0000000000004543

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anti-cd19-chimeric-antigen-receptor-t-cell-therapy-tianjin-mycure-medical-technology. Reactions Weekly 1946, 40 (2023). https://doi.org/10.1007/s40278-023-34641-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-34641-y

Search

Navigation